IMMUNE CELLS ASSAY TO PREDICT C-PEPTIDE LOSS (DSB.AD001.056)

Area tematica

Scienze biomediche

Area progettuale

Struttura responsabile del progetto di ricerca

Istituto per l'endocrinologia e l'oncologia "Gaetano Salvatore" (IEOS)

Responsabile di progetto

MARIO GALGANI
Telefono: 0817464580
E-mail: mario.galgani@unina.it

Abstract

Type 1 Diabetes (T1D) is an autoimmune disease characterized by a T cell-mediated destruction of pancreatic b-cells. Immune cell subsets and circulating biological compounds at the interface between immune and metabolic pathways are considered to be involved in the progression of b-cell failure. To date, few studies have investigated the involvement of metabolic/inflammatory factors in the early stages of T1D. In addition, none of the previously mentioned studies examined inflammatory/metabolic and immune parameters able to predict residual b-cell function over time and monitor the metabolic and immunological status characterizing the disease. In our previous study We identified a specific meta-immunological profile associated to disease status and immune cell populations able to predict residual cell function over time. Our proposal aims at verifying the internal precision of our assay (citofluorimetric analysis of CD3+CD16+CD56+ T cells and CD1c+CD19-CD14-CD303- type 1 mDC1s), through the analysis of blinded replicated testing in collaboration with Core and Validation Center (CAV) at Benaroya Research Institute (Seattle, USA).

Obiettivi

Confermare la validità e la precisione interna di un saggio biologico che prevede l'analisi di due specifiche popolazioni del sangue periferico: i linfociti CD3+CD16+CD56+ e le cellule dendritiche mieloidi di tipo 1 CD1c+CD19-CD14-CD303- .

Data inizio attività

01/08/2015

Parole chiave

TYPE 1 DIABETES, BIOMARKERS, IMMUNE RESPONSE

Ultimo aggiornamento: 02/01/2025